Search

everythinglearnresearchcommunity

for

Search:↓

Acne is not a key diagnostic feature for PCOS, postadolescent men with acne may have insulin resistance, melanoma patients often have few moles, tumor size in CSCC indicates higher risk of serious outcomes, and hidradenitis suppurativa is linked to higher risk of heart problems and death.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Skin problems like psoriasis and systemic sclerosis can increase the risk of heart disease, so doctors should watch for heart risks in patients with these conditions.

Gene therapy has potential as a future treatment for Hutchinson-Gilford progeria syndrome.

Medications for PCOS don't seem to raise heart disease risk.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

The bulletin provides guidelines for diagnosing and managing PCOS, suggesting weight loss, hormonal contraceptives, and diabetes screening, with clomiphene for infertility and various treatments for excess hair.

Insulin resistance in women with PCOS can lead to serious health issues, but lifestyle changes and certain medications can help manage symptoms.

Spironolactone helps reduce hospital visits and death from heart issues, lowers blood pressure, but has unclear effects on heart failure with normal heart pump function and can cause high potassium and breast enlargement in men.

Minoxidil solution safely and effectively treats hair loss.

Cushing's syndrome can cause serious health problems, and early treatment is crucial, but some issues may remain after treatment.

The guidelines suggest lifestyle changes, diet adjustments, and personalized medication to manage dyslipidemia and reduce heart disease risk.

Obese and non-obese women with PCOS have higher heart risk markers, especially if they are obese.

Some hair loss and prostate drugs might increase the risk of diabetes and heart disease.

Diagnose and manage hair issues in women by checking medical conditions and using personalized treatments.

Women with PCOS have a higher risk of metabolic syndrome and need lifestyle changes and treatment.

The document concludes that early diagnosis and treatment of PCOS in teenagers is important for managing symptoms and preventing long-term health problems.

Women experience more side effects and have worse blood pressure control from hypertension treatments than men, despite using different medications.

Mesenchymal stem cells could help treat aging-related diseases better than current methods.

People with cutaneous Lichen Planus are more likely to have Metabolic Syndrome and related conditions like high cholesterol, diabetes, and high blood pressure.

The document concludes that future heart disease research should account for sex-specific differences to improve diagnosis, treatment, and outcomes.

Using existing drugs for new purposes could be a cost-effective way to treat chest pain and non-clogged heart arteries, with some drugs for lung blood pressure showing promise but needing more testing.

Compounds from Alpinia zerumbet may help with hair regrowth and cancer treatment by targeting PAK1.

Hormone therapy for trans individuals is effective and generally safe in the short term.

Eating disorders like anorexia and bulimia cause skin problems, and dermatologists can help detect these disorders early for better treatment outcomes.

Male hormones, or androgens, affect women's health in areas like mood and bone density, and hormone replacement therapy using antiandrogenic progestogens can improve mood disorders and alertness in menopausal women.

Relatives of women with PCOS symptoms are more likely to have similar health issues.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

Some patients taking finasteride or dutasteride may have ongoing sexual problems and depression even after stopping the medication.

A specific drug can help treat Lichen Planopilaris, a condition causing permanent hair loss.